Comparative Pharmacology
Head-to-head clinical analysis: GEMIFLOXACIN MESYLATE versus MOXIFLOXACIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GEMIFLOXACIN MESYLATE versus MOXIFLOXACIN HYDROCHLORIDE.
GEMIFLOXACIN MESYLATE vs MOXIFLOXACIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, blocking DNA replication and transcription.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication, transcription, repair, and recombination.
320 mg orally once daily for 7-14 days
400 mg orally or intravenously once daily for most indications; duration varies by indication.
None Documented
None Documented
Terminal elimination half-life 7–9 hours (mean 8.2 h) in healthy adults; prolonged in renal impairment (e.g., 15–22 h in severe renal impairment).
Terminal elimination half-life is approximately 12-14 hours in healthy adults, allowing once-daily dosing. This is extended in severe renal impairment (creatinine clearance <30 mL/min) and in the elderly.
Renal: ~61% as unchanged drug, ~7% as glucuronide; Fecal/biliary: ~28% as unchanged drug and metabolites.
Approximately 20% of a dose is excreted unchanged in urine, with about 25% recovered as a glucuronide conjugate (M1) and a sulfate conjugate (M2). Biliary/fecal excretion accounts for about 55% of the dose, with a portion undergoing enterohepatic recirculation.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic